CAS: 4810-41-7; N,N-Dimethylpyridine-3-Sulfonamide

该化合物是一种磺酰胺衍生物,在3号站点以二甲基氨基磺酰基组替代了一种环状,该化合物因其作为建筑块或中间体的多功能性,对有机合成和制药研究感兴趣,该化合物的离子磺酰胺组和基本丙烯氮有助于其在核循环替代反应和金属催化转化中的用途,在各种条件下,其明确界定的结构和稳定性使其适合在药用化学中应用,特别是在生物活性分子的开发中,该化合物通常在标准实验室条件下处理,并适当防范磺酰胺衍生物.

结构式图片

相似化合物

4810-41-7 852388-77-3 4847-34-1

上下游产品

Pyridine-3-sulfonyl chloride N,N-Dimethyltrimethylsilylamine

合成工艺路线路线简述

    📜吡啶-3-磺酰氯,N,N-二甲基三甲基硅胺 以 乙腈 作为反应溶剂,化学反应 1.0H,以99%的收率获得产物n,N-二甲基砒啶-3-磺酰胺
    参考文献:Preparation Of Sulfonamides From N-Silylamines
    标题:Preparation Of Sulfonamides From N-Silylamines
    摘要:Sulfonamides Have Been Prepared In High Yields By The Reactions Of N-Silylamines With Sulfonyl Chlorides And Fluorides. In A Competition Experiment,The Sulfonyl Chlorides Were Found To Be Far More Reactive Than Sulfonyl Fluorides. The Chemistry May Be Used To Prepare Aliphatic,Aromatic,Tertiary,Secondary,And Primary Sulfonamides. It May Also Be Done In The Absence Of Solvent And The Byproduct Trimethylsilyl Chloride Recovered In Good Yield. Primary Sulfonamides Were Synthesized From The Sulfonyl Chloride With Aminotriphenyl Silane (Ph3Sinh2),A Conversion Demonstrated With The Synthesis Of The Carbonic Anhydrase Inhibitor,Acetazolamide. (C) 2013 Elsevier Ltd. All Rights Reserved.
    DOI:10.1016/j.Tetlet.2013.08.034

    海关参考信息

    专利信息


    专利号:WO-2023191400-A1
    优先权日:2022-04-01
    标题:Ethyl piperidine triazolo triazine derivatives, synthesis method therefor, and pharmaceutical composition containing same for prevention or treatment of cancer
    发明人:JI SEUNGHEE; BYUN JOONSEOK; KIM JIWON; KIM DOYOUNG; KIM SEOHYUN; LEE JONGHYUN; JUNG SEUNGHEE; CHOI JONGRYOUL; KO DONG-HYUN; KIM DONGKYU; SON SEO HYUN; KANG JI YOON; JANG HYU JEONG; AHN SANG YEOP; KIM JI YONG; LEE SEO JIN
    权利人:HK INNO N CORP; FUTURE MEDICINE CO LTD
    摘要:The present invention relates to an ethyl piperidine triazolo triazine derivative, a synthesis method therefor, and a pharmaceutical composition including same for the prevention or treatment of cancer. Acting as an antagonist on an adenosine A2A receptor (A2AR), the derivative can exhibit efficacy for the prevention or treatment of various A2AR-related diseases, specifically, various cancers. When used in combination therapy with an immune checkpoint inhibitor, the derivative is expected to exhibit a remarkable synergistic effect in terms of anticancer activity.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1101/2024.04.29.591684
    摘要:Lithgo RM, Tomlinson CWE, Fairhead M, Winokan M, Thompson W, Wild C, Aschenbrenner JC, Balcomb BH, Marples PG, Chandran AV, Golding M, Koekemoer L, Williams EP, Wang S, Ni X, MacLean E, Giroud C, Godoy AS, Xavier MA, Walsh M, Fearon D, von Delft F. Crystallographic Fragment Screen of Coxsackievirus A16 2A Protease identifies new opportunities for the development of broad-spectrum anti-enterovirals. bioRxiv. 2024 Apr 29;().
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知